Jubilant Pharmova Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| JUBLPHARMA.NS | TEVA | MOREPENLAB.NS | GLENMARK.NS | GRANULES.BO | AJANTPHARM.NS | |
|---|---|---|---|---|---|---|
| Market cap | 150.02B | 48.91B | 53.21B | 700.43B | 192.80B | 410.13B |
| P/E (TTM) | 42.7 | 97.5 | 28.3 | 39.0 | 35.3 | 32.5 |
| Forward P/E | 18.7 | 13.5 | — | 25.6 | 26.5 | 27.9 |
| Price/book | 2.1 | 6.1 | 3.9 | 6.7 | 4.8 | 8.4 |
| Dividend yield | 0.53% | — | 0.20% | 0.20% | 0.26% | 1.93% |
| 1-year change | −19.07% | +71.10% | +113.46% | +38.35% | +0.63% | +29.11% |
| Today | +0.80% | +0.16% | −4.17% | −0.91% | −0.01% | −1.04% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All JUBLPHARMA.NS news ›Jubilant Pharmova Board Approves Issuance of Non-Convertible Debentures up to ₹800 Crore
Jubilant Pharmova Limited has announced that its Board of Directors, at its meeting held on October 12, 2026, approved the issuance of Non-Convertible Debentures (NCDs) on a private placement basis. 12 Oct 2026, 01:33 PM IST Equity Bulls…
More from 1 other outlet
Jubilant Pharmova eyes $150 million through rupee debt sale, bankers say
Jubilant Pharmova is set to raise funds through a rupee bond offering, primarily to invest in capital expenditure, two merchant bankers said on Friday. The company is engaged in specialty pharmaceuticals, contract development and…
More from 1 other outlet
Jubilant Pharmova Limited Declares Dividend for the Financial Year Ended March 31, 2026
Jubilant Pharmova Limited announced at the AGM held on August 26, 2026, declared Dividend of INR 5 per equity share of the face value of INR 1 each for the Financial Year ended March 31, 2026.... Jubilant Pharmova Limited Declares Dividend…
Jubilant Pharmova Limited Receives Rectification Order from Income Tax Department Deleting Tax Demand of INR 221.0 Million
Jubilant Pharmova Limited had preferred rectification application against certain tax demands raised by the Income Tax Department for Assessment Year 2020-21. Pursuant to rectification orders... Jubilant Pharmova Limited had preferred…
Transcript : Jubilant Pharmova Limited, Q4 2026 Earnings Call, May 22, 2026
Presentation Operator MessageOperator Ladies and gentlemen, good day, and welcome to Jubilant Pharmova Limited's Q4 and full year FY '26 Earnings Webinar. [Operator Instructions] Please note that Transcript : Jubilant Pharmova Limited, Q4…
Jubilant Pharmova Board Approves Rs 800 Cr NCD Issue
Jubilant Pharmova's board approved issuing non-convertible debentures (NCDs) worth Rs 800 crore via private placement, with shareholder approval sought for up to Rs 2,500 crore. Key PointsJubilant Pharmovas board approved issuing…
Quant MF sells Jubilant Pharmova stake for over ₹100 crore; stock falls over 2%
Quant Mutual Fund has sold nearly 1 per cent stake in Jubilant Pharmova for over ₹100 crore through an open market transaction, according to NSE data. Quant Mutual Fund (Quant MF) offloaded 11 lakh shares, representing a 0.69 per cent…
More from 1 other outlet
Jubilant Pharmova approves ₹800 crore NCD issue through private placement
Jubilant Pharmova has approved an NCD issue of up to ₹800 crore through private placement, with the debentures proposed to be listed on the BSE. Jubilant Pharmova Ltd on Monday said its Board of Directors has approved the issuance of…
Sensex, Nifty Today LIVE: NSE Stock Market Updates, Oct 12, 2026: Goodluck India plans corporate restructuring, amalgamations | Jubilant Pharmova issuing ₹800 crore debentures
Goodluck India expands its corporate restructuring to include its subsidiary in an amalgamation plan, representing a strategic consolidation effort. Jubilant Pharmova Limited plans to issue Non-Convertible Debentures worth up to ₹800 crore…
How Can Jubilant Pharmova Be a “Contra Bet” to the US Pharma Tariff?
The article outlines the industry headwind and the company being a contra bet to the headwind, which is an integrated global pharmaceuticals company having three business segments which are pharmaceuticals, contract research and…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com13
- businessupturn.com7
- thehindubusinessline.com3
- equitybulls.com2
- sahi.com2
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 33 articles, not a forecast.